Literature DB >> 29916288

BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.

Hein Than1, Weng K Lye2, Colin Sng1, John C Allen2, S Tiong Ong1,3,4,5, Charles Chuah1,3.   

Abstract

Entities:  

Year:  2018        PMID： 29916288     DOI： 10.1080/10428194.2018.1461863

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma.

Authors:  Jeff D Wang; Samuel G Katz; Elizabeth A Morgan; David T Yang; Xueliang Pan; Mina L Xu
Journal:  Hum Pathol       Date:  2019-08-16       Impact factor: 3.466

Review 2.  Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Authors:  Susan Branford; Dennis Dong Hwan Kim; Jane F Apperley; Christopher A Eide; Satu Mustjoki; S Tiong Ong; Georgios Nteliopoulos; Thomas Ernst; Charles Chuah; Carlo Gambacorti-Passerini; Michael J Mauro; Brian J Druker; Dong-Wook Kim; Francois-Xavier Mahon; Jorge Cortes; Jerry P Radich; Andreas Hochhaus; Timothy P Hughes
Journal:  Leukemia       Date:  2019-06-17       Impact factor: 11.528

3.  Compound Kushen Injection Protects Skin From Radiation Injury via Regulating Bim.

Authors:  Jianxiao Zheng; Gong Li; Juanjuan Wang; Shujing Wang; Qing Tang; Honghao Sheng; Wanyin Wu; Sumei Wang
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.